Incretin Atlas › Trials › SURPASS-CVOT
SURPASS-CVOT
Tirzepatide · T2D + established ASCVD
Design
- Molecule(s)
- Tirzepatide
- Population
- T2D + established ASCVD
- Official title
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed · 2020-05 → 2025-06
- Participants
- 13299
- Registry
- NCT04255433
Cardiovascular and kidney outcomes
SURPASS-CVOT tirzepatide 5–15 mg vs dulaglutide 1.5 mg (active) · T2D + established ASCVD · n = 13299 · 2025 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE (vs dulaglutide) primary Composite of death from cardiovascular causes, myocardial infarction, or stroke (95.3% CI reported, adjusted for interim analysis) | 0.92 | 0.83–1.01 | 801 vs 862 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.89 | 0.77–1.02 | 367 vs 408 | verified |
| All-cause death Death from any cause | 0.84 | 0.75–0.94 | 566 vs 669 | verified |
| Myocardial infarction Myocardial infarction (the text does not specify fatal or non-fatal; component of primary composite) | 0.86 | 0.74–1.00 | 311 vs 357 | verified |
| Stroke Stroke (the text does not specify fatal or non-fatal; component of primary composite) | 0.91 | 0.76–1.09 | 229 vs 249 | verified |
| CV death or worsening HF Composite of death from cardiovascular causes or hospitalization or urgent visit for heart failure | 0.91 | 0.81–1.03 | 512 vs 557 | verified |
| Expanded MACE (MACE + revasc.) 4-point composite: death from CV causes, myocardial infarction, stroke, or coronary revascularization (secondary end point); comparator dulaglutide 1.5 mg (active control) | 0.88 | 0.81–0.96 | 1089 vs 1217 | verified |
Verbatim quotes (7)
- 3-point MACE (vs dulaglutide) · Abstract; Results, paragraph 1; Table 2
A primary end-point event occurred in 801 patients (12.2%) in the tirzepatide group and 862 (13.1%) in the dulaglutide group (hazard ratio, 0.92; 95.3% confidence interval, 0.83 to 1.01
- Cardiovascular death · Results, paragraph 1; Table 2
Death from cardiovascular causes occurred in 367 patients (5.6%) in the tirzepatide group and 408 (6.2%) in the dulaglutide group (hazard ratio, 0.89; 95% CI, 0.77 to 1.02).
- All-cause death · Results, paragraph 1; Table 2
Death from any cause occurred in 566 patients (8.6%) in the tirzepatide group and 669 (10.2%) in the dulaglutide group (hazard ratio, 0.84; 95% CI, 0.75 to 0.94)
- Myocardial infarction · Results, paragraph 1; Table 2
Myocardial infarction occurred in 311 patients (4.7%) and 357 patients (5.4%), respectively (hazard ratio, 0.86; 95% CI, 0.74 to 1.00).
- Stroke · Results, paragraph 1; Table 2
Stroke occurred in 229 patients (3.5%) and 249 patients (3.8%), respectively (hazard ratio, 0.91; 95% CI, 0.76 to 1.09).
- CV death or worsening HF · Results, paragraph 1; Table 2
Death from cardiovascular causes or hospitalization or urgent visit for heart failure ... occurred in 512 patients (7.8%) in the tirzepatide group and 557 (8.5%) ... (hazard ratio, 0.91; 95% CI, 0.81 to 1.03)
- Expanded MACE (MACE + revasc.) · Table 2, key secondary end points
| Death from cardiovascular causes, myocardial infarction, stroke, or coronary revascularization — no. (%) | 1089 (16.5) | 1217 (18.5) | 0.88 (0.81 to 0.96) |
Primary sources
- Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. PMID: 41406444.
- Eli Lilly and Company. The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT) (SURPASS-CVOT). ClinicalTrials.gov identifier NCT04255433. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04255433
- SURPASS-CVOT: clinically relevant trial insights [session]. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Available from: https://docs.mdwrt.app/infographics/easd-2026-congress-intelligence/
How to cite this page
Medical Adviser's Group. Incretin Atlas: SURPASS-CVOT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surpass-cvot/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.